Sugi Predict

Sugi Predict / Compounds / SCHEMBL4912893

SCHEMBL4912893

SCHEMBL4912893

COC(=O)c1ccccc1Oc1ncc(Cl)cc1N

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ KMT2A Q03164 3/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ ABL1 P00519 1/20 0.50
▸ CFTR P13569 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ CYP2C9 P11712 3/20 0.47
▸ CYP2C19 P33261 3/20 0.47
▸ CYP1A2 P05177 2/20 0.47
▸ CYP3A4 P08684 2/20 0.47
▸ CCR2 P41597 2/20 0.47
▸ CCR4 P51679 2/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CCR5 P51681 1/20 0.47
▸ SLC6A3 Q01959 2/20 0.45
▸ SLC6A4 P31645 1/20 0.45
▸ GAA P10253 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ GLA P06280 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4902844 0.82 L3MBTL1 (0.43) ALDH1A1ABL1CFTRCYP2C9CYP2C19
SCHEMBL4909376 0.81 CCR2 (0.49) ABL1CYP2C19CYP1A2CYP3A4CCR2
SCHEMBL4910090 0.81 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2KMT2AMEN1CYP2C9
SCHEMBL15235338 0.80 ABL1 (0.61) ALDH1A1SMN1; SMN2KMT2AMEN1ABL1
SCHEMBL18284643 0.80 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2KMT2AMEN1CYP2C9
SCHEMBL17047605 0.80 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2KMT2AMEN1ABL1
SCHEMBL1135451 0.79 TDP1 (0.59) ALDH1A1SMN1; SMN2KMT2AMEN1CFTR
SCHEMBL4909330 0.78 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2ABL1HSD17B10CYP2C9
SCHEMBL14006333 0.78 CYP1A2 (0.49) ALDH1A1SMN1; SMN2KMT2AMEN1CYP2C9
SCHEMBL4911339 0.78 L3MBTL1 (0.54) ABL1CCR2PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3345899-B1 BENZOFURAN-2-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN INC (US) 2020-02-19 — — EP disclosed
EP-3345899-B1 BENZOFURAN-2-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN INC (US) 2020-02-19 — — EP disclosed
EP-3345899-A1 BENZOFURAN-2-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS Allergan, Inc. (US) 2018-07-11 — — EP disclosed
EP-3345899-A1 BENZOFURAN-2-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS Allergan, Inc. (US) 2018-07-11 — — EP disclosed
EP-2820010-B1 BENZOFURAN-2-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN INC (US) 2018-05-09 — — EP disclosed
EP-2820010-B1 BENZOFURAN-2-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN INC (US) 2018-05-09 — — EP disclosed
US-9550746-B2 Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators ALLERGAN, INC. (US) 2017-01-24 — — US disclosed
US-9416120-B2 Benzofuran-2-sulfonamides pyridine derivatives as chemokine receptor modulators ALLERGAN, INC. (US) 2016-08-16 — — US disclosed
US-9416120-B2 Benzofuran-2-sulfonamides pyridine derivatives as chemokine receptor modulators ALLERGAN, INC. (US) 2016-08-16 — — US disclosed
US-9416120-B2 Benzofuran-2-sulfonamides pyridine derivatives as chemokine receptor modulators ALLERGAN, INC. (US) 2016-08-16 — — US disclosed
US-8815915-B2 Benzofuran-2-sulfonamides pyridine derivatives as chemokine receptor modulators ALLERGAN, INC. (US) 2014-08-26 — — US disclosed
WO-2013130958-A1 BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-09-06 — — WO disclosed
WO-2013130962-A1 BENZOFURAN- 2 - SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-09-06 — — WO disclosed
US-20130231339-A1 BENZOFURAN-2-SULFONAMIDES PYRIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-09-05 — — US disclosed
US-20130231338-A1 BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-09-05 — — US disclosed
US-20130231339-A1 BENZOFURAN-2-SULFONAMIDES PYRIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-09-05 — — US disclosed
US-20130231339-A1 BENZOFURAN-2-SULFONAMIDES PYRIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-09-05 — — US disclosed
US-20080293720-A1 Pyridinyl Sulfonamide Modulators of Chemokine Receptors GLAXO GROUP LIMITED (GB) 2008-11-27 — — US disclosed
US-20080293720-A1 Pyridinyl Sulfonamide Modulators of Chemokine Receptors GLAXO GROUP LIMITED (GB) 2008-11-27 — — US disclosed
US-20080293720-A1 Pyridinyl Sulfonamide Modulators of Chemokine Receptors GLAXO GROUP LIMITED (GB) 2008-11-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231339-A1 BENZOFURAN-2-SULFONAMIDES PYRIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS CCR2, CXCR2, CXCR4 ALDH1A1 2064/4885SMN1; SMN2 3781/4885KMT2A 4639/4885
US-20080293720-A1 Pyridinyl Sulfonamide Modulators of Chemokine Receptors CCR2, CCR1, CCRL2 ALDH1A1 1334/4885SMN1; SMN2 2031/4885KMT2A 3726/4885
US-20130231338-A1 BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS CXCR2, CCR2, CCR5 ALDH1A1 1991/4885SMN1; SMN2 3932/4885KMT2A 4572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.